Evidence map›Paper›PMID 40616466›Full record

SynthesisMolecular pain

Seeking the root causes of menstrual pain: A systematic review of biomarkers in menstrual effluent.

Chandrashekara N Kyathanahalli, Frank F Tu, Gabriela Ashenafi, Margaret S Schroer, Kevin M Hellman

Abstract readSystematic Review
In one paragraph

Synthesis in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Severe menstrual pain is not normal: adolescent dysmenorrhoea as a marker of future chronic pain.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chandrashekara N KyathanahalliDepartment of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.
Frank F TuDepartment of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.
Gabriela AshenafiDepartment of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.
Margaret S SchroerDepartment of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.
Kevin M HellmanDepartment of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.ORCID 0000-0001-9420-5602

Funding

Early Menstrual Pain Impact on Multisensory HypersensitivityR01HD096332 · NICHD · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI TU, FRANK FU-SHENG · 2018 to 2023
$3.6M
Mechanistic Characterization of Uterine Pain (M-CUP) to improve diagnosis and treatment for dysmenorrheaR01HD098193 · NICHD · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI HELLMAN, KEVIN · 2019 to 2023
$2.8M
NICHD NIH HHS R01 HD096332NICHD NIH HHS R01 HD098193
6 · The paper itself

Abstract

Dysmenorrhea (period pain) affects over 40% of women and is a leading cause of missed school and workdays. However, the molecular mechanisms underlying this pain are not fully understood. We conducted a systematic review (Prospero registration: CRD42024535081) to identify and evaluate the biomolecules in menstrual effluent that may contribute to dysmenorrhea and assess how non-hormonal medications (e.g. NSAIDs) impact these biomarkers. Fifteen studies involving two hundred twenty-three participants met the inclusion criteria. We used the Newcastle-Ottawa Scale (for observational studies) and the Cochrane RoB2 tool (for randomized controlled trials) to evaluate the risk of bias and the quality of studies. Eight studies consistently reported elevated prostaglandin levels in the menstrual effluent of women with dysmenorrhea, though sample sizes were generally small, and methodological issues were noted. Seven studies demonstrated that NSAIDs reduce prostaglandin concentrations; however, these trials utilized multiple-day dosing protocols instead of single-dose regimens, leaving questions about acute treatment effects. Two studies highlighted alternative molecular targets, such as 12-HETE and platelet-activating factor (PAF), that may also play key roles in menstrual pain. Overall, elevated prostaglandins are a recurring finding, but the limited scope and design of existing studies indicate a need for larger, methodologically rigorous investigations. Nevertheless, the few studies that identified molecules other than prostaglandins suggest there are viable druggable targets for clinical trials to reduce menstrual pain.

Indexed as

BiomarkersDysmenorrheaMenstruationAnti-Inflammatory Agents, Non-SteroidalFemaleHumansProstaglandinsAnti-Inflammatory Agents, Non-SteroidalBiomarkersProstaglandinsChronic nonpelvic paineicosanoidsnon-steroidal anti-inflammatory drugsprimary dysmenorrheaprostaglandinssystematic review

Identifiers

PMID40616466
PMCPMC12374046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.